ArticleCancer prevention research (Philadelphia, Pa.)2010
A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma.
Article in Cancer prevention research (Philadelphia, Pa.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 1 synthesis or guideline pooled it, 157 citations in OpenAlex.
- ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.The American journal of gastroenterology · 2016Guideline
- MyClone: rapid and precise reconstruction of clonal population structures for tumors.BMC bioinformatics · 2025Article
- Genomic landscape and immunological profile of glioblastoma in East Asian patients.Cell reports. Medicine · 2025Article
- Evolutionary measures show that recurrence of DCIS is distinct from progression to breast cancer.Breast cancer research : BCR · 2025Article
- Single-cell copy number calling and event history reconstruction.Bioinformatics (Oxford, England) · 2025Article
- Article
- Evolutionary Measures Show that Recurrence of DCIS is Distinct from Progression to Breast Cancer.medRxiv : the preprint server for health sciences · 2024Article
- Degree of crypt atypia correlates with progression to high-grade dysplasia/adenocarcinoma in non-dysplastic Barrett's oesophagus.Histopathology · 2023Article
- Article
- Toward a systems-level probing of tumor clonality.iScience · 2023Review
- An Integrative Analysis of Nasopharyngeal Carcinoma Genomes Unraveled Unique Processes Driving a Viral-Positive Cancer.Cancers · 2023Article
- High-throughput characterization of mutations in genes that drive clonal evolution using multiplex adaptome capture sequencing.Cell systems · 2021Article
- A new method to accurately identify single nucleotide variants using small FFPE breast samples.Briefings in bioinformatics · 2021Article
- Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas.Nature communications · 2021Article
- Evolving insights: how DNA repair pathways impact cancer evolution.Cancer biology & medicine · 2020Review
- Inference of mutability landscapes of tumors from single cell sequencing data.PLoS computational biology · 2020Article
- Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trial.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2020Article
- Application of simultaneous selective pressures slows adaptation.Evolutionary applications · 2020Article
- When, why and how tumour clonal diversity predicts survival.Evolutionary applications · 2020Article
- Joint single cell DNA-seq and RNA-seq of gastric cancer cell lines reveals rules ofNAR genomics and bioinformatics · 2020Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Neoplastic progression is an evolutionary process driven by the generation of clonal diversity and natural selection on that diversity within a neoplasm. We hypothesized that clonal diversity is associated with risk of progression to cancer. We obtained molecular data from a cohort of 239 participants with Barrett's esophagus, including microsatellite shifts and loss of heterozygosity, DNA content tetraploidy and aneuploidy, methylation, and sequence mutations. Using these data, we tested all major diversity measurement methods, including genetic divergence and entropy-based measures, to determine which measures are correlated with risk of progression to esophageal adenocarcinoma. We also tested whether the use of different sets of loci and alterations to define clones (e.g., selectively advantageous versus evolutionarily neutral) improved the predictive value of the diversity indices. All diversity measures were strong and highly significant predictors of progression (Cox proportional hazards model, P < 0.001). The type of alterations evaluated had little effect on the predictive value of most of the diversity measures. In summary, diversity measures are robust predictors of progression to cancer in this cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.